Market Introduction
Anaphylaxis is an allergic reaction that can further lead to a fatal condition known as anaphylactic shock. Anaphylaxis occurs when the patient's body reacts to a foreign substance and produces a high amount of histamine that triggers an inflammatory response. It is a severe, life threatening allergic reaction marked by indications such as swallowing and breathing difficulties, skin itching, and lowering blood pressure.
Thus, the rising incidence of anaphylaxis is expected to create a significant demand for anaphylaxis treatment in the coming years, which is further anticipated to drive the anaphylaxis treatment market.
The outbreak of COVID–19 has severely impacted the flow of medical services in the region. Also, the countries are popular for medical tourism, which is also affected by the pandemic. Brazil, Argentina, Peru, Chile, Uruguay, Colombia are affected by the second wave of corona infection. Among which Brazil has registered the majority of the deaths. As of May 2021, around 411,854 lives have already been lost in Brazil, which is a sign of the second wave of COVID19 infection. It is expected that the region is likely to impose a second lockdown, which will eventually hamper the healthcare industry in the region. Moreover, countries are significantly dependent on the US and European countries for their medical resources. Thus, the region's market has experienced a significant slowdown and is expected to face the same in the following one to two years. Additionally, people in Brazil became more aware of the risk of aggravating asthma or allergic diseases due to COVID-19, along with its treatments, which is leading to boost the growth of the anaphylaxis treatment market in the rest of the world. These factors had a potential impact on the South and Central America anaphylaxis treatment market.
Market Overview and Dynamics
The Anaphylaxis treatment market in South and Central America is expected to grow from US$ 91.9 million in 2021 to US$ 157.5 million by 2028; it is estimated to grow at a CAGR of 8.0% from 2021 to 2028. Cases of allergies have been observed after the COVID-19 vaccination. Along with this, patients with an anaphylaxis history should carry an epinephrine autoinjector to bring it to their vaccination appointment. Along with this initiative, COVID-19 vaccination places should have always at least three doses of epinephrine ready, along with the capability to replace supplies after epinephrine is administered to a patient. Nevertheless, anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. These factors present an opportunity for the growth of the anaphylaxis treatment market in the current COVID-19 scenario.
Key Market Segments
In terms of medication type, the epinephrine segment accounted for the largest share of the South and Central America anaphylaxis treatment market in 2020. In terms of route of administration, the parenteral segment accounted for the largest share of the South and Central America anaphylaxis treatment market in 2020. In terms of allergy type, the food allergy segment accounted for the largest share of the South and Central America anaphylaxis treatment market in 2020. In terms of distribution channel, the retail pharmacies segment held a larger market share of the anaphylaxis treatment market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the anaphylaxis treatment market in South and Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Amneal Pharmaceuticals Inc., Mylan N.V., Abbott, Pfizer Inc., Glaxosmithkline Plc., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., and ALK-ABELLó.
Reasons to buy report
- To understand the South and Central America anaphylaxis treatment market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for South and Central America anaphylaxis treatment market
- Efficiently plan M&A and partnership deals in South and Central America Anaphylaxis treatment market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form South and Central America Anaphylaxis treatment market
- Obtain market revenue forecast for market by various segments from 2021-2028 in South and Central America region.
SOUTH AND CENTRAL AMERICA ANAPHYLAXIS TREATMENT MARKET SEGMENTATION
By Medication Type
- Epinephrine
- Antihistamines
- Steroids
- Beta-Agonist
- Others
By Route of Administration
- Parenteral
- Oral
- Others
By Allergy Type
- Food Allergy
- Medications
- Insect Stings
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
-
South and Central America
- Brazil
- Argentina
- Rest of South and Central America
Companies Mentioned
- Amneal Pharmaceuticals Inc.
- Mylan N.V.
- Abbott
- Pfizer Inc.
- Glaxosmithkline Plc.,
- Merck And Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ALK-ABELLó
South and Central America Anaphylaxis Treatment Market Strategic Insights
South and Central America Anaphylaxis Treatment Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 91.9 Million |
| Market Size by 2028 | US$ 157.5 Million |
| CAGR (2021 - 2028) | 8.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Medication Type
|
|
Regions and Countries Covered
|
|
| South and Central America | Brazil, Argentina, Rest of South and Central America |
| Market leaders and key company profiles |
|
South and Central America Anaphylaxis Treatment Market Country and Regional Insights
